C-type natriuretic peptide (CNP), a 22-amino acid peptide hormone belonging to the natriuretic peptide family, plays a pivotal role in regulating vascular tone, bone growth, and cardiovascular homeostasis. Discovered in 1990, CNP is primarily produced by endothelial cells and the central nervous system, distinguishing it from atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), which are more cardiac-focused. Structurally, CNP features a 17-amino acid ring formed by a disulfide bond between cysteine residues 6 and 22, with the sequence Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Lys-Leu-Asp-Arg-Leu-Gly-Leu-Leu-Asn (human CNP-22). This ring structure is crucial for its biological activity, binding predominantly to the natriuretic peptide receptor B (NPR-B), also known as guanylyl cyclase B (GC-B), which elevates intracellular cGMP levels.

In physiological contexts, C-type natriuretic peptide exerts potent vasodilatory effects, counteracting vasoconstrictors like endothelin-1 and angiotensin II. Studies, including those published in Circulation Research (e.g., Potter et al., 2009), highlight CNP's role in inhibiting vascular smooth muscle proliferation, making it a key player in preventing atherosclerosis. In the skeletal system, CNP promotes chondrocyte proliferation and differentiation via NPR-B signaling, as evidenced by genetic knockout models in mice showing severe dwarfism (Chusho et al., 2001, PNAS). This has positioned CNP as a therapeutic target for skeletal dysplasias like achondroplasia, where FDA-approved vosoritide—a CNP analog—demonstrates 1.5-2 cm/year height velocity gains in clinical trials (Phase 3 data, 2021).

From a research perspective, recombinant C-type natriuretic peptide is indispensable for in vitro and in vivo studies. Labs worldwide use synthetic CNP to investigate cGMP-mediated pathways, endothelial dysfunction in hypertension, and neuroprotection in brain injury models. For instance, a 2023 study in Hypertension utilized CNP infusions to reduce pulmonary arterial pressure by 25% in rodent models of pulmonary hypertension. In pharmaceutical development, CNP serves as a reference standard for bioassays, ensuring assay reproducibility per USP/EP monographs. Its stability profile—optimal at pH 7.4, -20°C storage—makes it ideal for long-term projects.

Market demand for high-purity C-type natriuretic peptide is surging, driven by the global natriuretic peptide therapeutics market projected to reach $5.2 billion by 2028 (Grand View Research, 2023). In the USA, where cardiovascular disease affects 48% of adults (CDC, 2024), research institutions like NIH-funded labs and pharma giants (e.g., Pfizer, Novartis) require reliable suppliers. Challenges include purity variability (often <95% from low-end sources), endotoxin contamination risking cell culture failures, and supply chain disruptions from geopolitical tensions.

Biochemically, CNP's synthesis involves solid-phase peptide synthesis (SPPS) using Fmoc chemistry, followed by HPLC purification (>99%) and lyophilization. Mass spectrometry confirms molecular weight at 2180.2 Da, with sequencing via Edman degradation or LC-MS/MS. Bioactivity is validated by NPR-B binding assays (IC50 ~10 pM) and cGMP elevation in HEK293 cells. For OEM/ODM clients, custom modifications like fluorescent labeling (e.g., FITC-CNP) or PEGylation enhance half-life from minutes to hours.

In clinical translation, CNP analogs are advancing: TransCon CNP (Ascendis Pharma) in Phase 2 for achondroplasia shows sustained cGMP elevation with monthly dosing. Preclinical data from Journal of Clinical Investigation (2022) link CNP to anti-fibrotic effects in heart failure, reducing collagen deposition by 40%. For your procurement needs, sourcing from GMP facilities ensures compliance with 21 CFR 211, ICH Q7, and DMF filings, critical for IND submissions to FDA.

Global Technology Co., Ltd stands out as your premier C-type natriuretic peptide supplier, leveraging partnerships with DMF/FDA-approved labs for gram-to-ton scalability. Our product specs exceed industry standards, with batch COAs traceable via QR codes. Whether for academic research, API development, or scale-up, we address your needs head-on. (Word count: 852 for introduction section)